
Mini-Invasive Surgery Eases Hemorrhoid Pain Fast
'Thanks to advances in technology, all surgical approaches now aim to be as minimally invasive as possible,' said Vinson-Bonnet. 'However, before considering surgery, we prioritize medical treatment for hemorrhoidal disease — addressing intestinal transit disorders, particularly constipation, and educating patients on proper bowel habits.' Surgery is considered only when these measures fail to provide relief.
Until the 2000s, hemorrhoidectomy was the primary surgical treatment for hemorrhoidal disease. Since then, less painful alternatives have emerged, including nerve blocks and stapling all designed to avoid external incisions and reduce postoperative pain and recovery times.
One such option is the pudendal nerve block, which involves anesthetizing the pudendal nerve using a long-acting agent. This provides 12-24 hours of postoperative pain relief following hemorrhoid surgery. However, stool passage over the surgical site can still cause significant discomfort between days 3 and 10, and complete healing may take 6 weeks, Vinson-Bonnet noted.
In 1998, Antonio Longo, MD, colorectal surgeon from Italy, and director of the European Centre for Coloproctology and Pelvic Diseases in Vienna, Austria, introduced stapled hemorrhoidopexy. This surgical technique uses a circular stapler to remove a circumferential ring of rectal mucosa above the hemorrhoids, repositioning prolapsing internal hemorrhoids to their normal anatomical position.
'Although innovative, stapled hemorrhoidopexy has been linked to serious complications and is now often replaced by a simpler technique that uses an anoscope to locate and ligate small rectal arteries,' said Vinson-Bonnet.
According to Vinson-Bonnet, these techniques are limited to internal hemorrhoids and are not appropriate for large external hemorrhoids and do not allow the removal of large external hemorrhoids, often caused by thrombosis, particularly after childbirth in women. Another drawback is recurrence, with symptoms returning to up to 20% of patients within 2 years.
'Thermofusion, which uses microwave energy to completely dry out internal bleeding, is an emerging technique. While still under evaluation, it is already being used in clinical practice,' she added. 'Other recent methods, such as radiofrequency — and, more rarely, laser — are also employed,' said Vinson-Bonnet.
Professor Émilie Duchalais, MD, PhD, digestive surgeon at Nantes University Hospital in Nantes, France, presented recent developments in minimally invasive treatment for fecal incontinence. She leads clinical and translational studies on this condition at the Institute of Digestive System Diseases.
'Sacral neuromodulation and Botox are two techniques mainly reserved for patients with fecal incontinence,' Duchalais explained. These are considered second- or third-line treatment options and are used only when medical treatment or rehabilitation has failed.
Sacral neuromodulation involves stimulating nerve roots near the sacrum, which engage in sphincter control and rectal sensitivity. 'Five to 10 years after implantation, long-term improvement is seen in 50%-70% of patients,' said Duchalais.
A major advantage of this method is that it allows a trial phase. Electrodes are temporarily implanted at the targeted site, enabling patients to evaluate the effectiveness of the treatment over 2-3 weeks. 'If the patient experiences at least a 50% reduction in incontinence episodes during this period, the device is permanently implanted. The system, similar to a pacemaker but placed in the buttocks, typically remains in place for at least 5 years, depending on the battery life,' she said.
'Urologists commonly use Botox to treat overactive bladder. Botox works by blocking acetylcholine, preventing muscle contractions, and reducing urinary leakage. In the rectum, Botox has a similar effect — blocking muscle activity and nerve signals to improve control in patients with fecal incontinence,' Duchalais noted.
Although effective, Botox provides only temporary relief. 'Its effects typically last 6-9 months. However, a recent study showed that after 5 years, patients required injections only once every 3 years on average,' she added.
Another approach currently under investigation is fat injection. 'Researchers are studying autologous fat injection into the anal sphincter as a potential treatment for urge incontinence. The technique aims to restore sphincter tone by harnessing the regenerative potential of stem cells found in fat tissue.' A clinical trial led by Rennes University Hospital, Rennes, France, is evaluating this method, and the early findings are promising. However, this approach remains experimental,' said Duchalais.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
HS market forecast to reach $7.8bn across 7MM by 2034
The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData. This 15.6% compound annual growth rate (CAGR) is largely attributed to the launch of novel biologics and small molecules targeting multiple inflammatory pathways beyond TNF-alpha inhibition. Currently, only three biologics are approved for HS: AbbVie's Humira (adalimumab), Novartis' Cosentyx (secukinumab), and UCB's Bimzelx (bimekizumab). While Humira, the first approved biologic, remains the market leader, it is widely viewed by KOLs as having limited efficacy, with response rates near 25%–30% and high rates of treatment fatigue. In contrast, the newer IL-17 inhibitors have demonstrated more robust outcomes. In pivotal trials (BE HEARD I/II), Bimzelx achieved hidradenitis suppurativa clinical response (HiSCR) rates of up to 64%, with a faster onset and more durable effect than Cosentyx, despite being a second-line biologic. However, candidiasis risk and high cost may temper uptake. The landscape is now shifting further with a maturing pipeline with varying mechanisms of action. MoonLake Immunotherapeutics' sonelokimab, a tri-specific nanobody targeting IL-17A/F and albumin, is anticipated to be a best-in-class agent based on its deeper tissue penetration and strong Phase II performance. Similarly, Incyte's JAK1 inhibitor povorcitinib is advancing through late-stage development, showing promise particularly in pain reduction and quality-of-life improvement metrics. GlobalData forecasts that by 2034, pipeline products, including sonelokimab and povorcitinib will represent 47.3% of the total HS market. A defining challenge in HS care remains the heterogeneity of disease severity and the high unmet need in both early- and late-stage disease. Diagnostic delays, averaging 7–10 years, often result in irreversible structural damage by the time patients reach speciality care. Furthermore, current treatments target only moderate-to-severe HS, leaving early-stage (Hurley stage I) patients without effective interventions. As highlighted by GlobalData's analysis, products that can safely intervene earlier in disease progression represent a significant commercial opportunity. KOLs also emphasised that clinical endpoints such as HiSCR50 do not fully capture the burden of disease, particularly in tunnel-dominant or refractory cases. As a result, next-generation trials are adopting stricter endpoints such as HiSCR75, and increasingly incorporating patient-reported outcomes such as dermatology life quality index (DLQI) and numerical rating scale-30 (NRS-30). This evolution in trial design aligns with payer and physician expectations for more meaningful, real-world benefits. Market growth will be led by the US, which accounted for over 70% of HS sales in 2024 due to a larger diagnosed population, broader biologic access, and premium pricing. While biosimilar entry may moderate TNF-alpha sales, the expansion of high-cost IL-17 and JAK pathway inhibitors is expected to intensify market competition and drive overall market prices upward due to the premium pricing of these agents. Barriers to market growth include safety monitoring requirements for JAK inhibitors, competition among newer biologics, and access challenges in countries with tighter reimbursement frameworks. However, if emerging therapies show consistent improvements in flare reduction, pain control, and psychosocial burden, as seen with Bimzelx and sonelokimab, they could reshape the treatment algorithm and expand biologic usage to earlier disease stages. With nearly 33 agents in active clinical development and multiple first-in-class mechanisms poised to enter the market, HS is undergoing a therapeutic transformation. GlobalData expects this evolution to redefine the standard of care for a historically underserved patient population. "HS market forecast to reach $7.8bn across 7MM by 2034" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.


Medscape
12 hours ago
- Medscape
Meet Barbie's Secret Weapon Against Type 1 Diabetes
Mattel, the US-based company behind the Barbie brand, launched its first Barbie doll designed with features of type 1 diabetes ( T1D). 'Introducing a Barbie doll with T1D marks an important step in our commitment to inclusivity and representation,' said Krista Berger, senior vice president of Barbie and global head of Dolls. 'Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love.' Rising Numbers T1D is a chronic autoimmune condition that affects millions of individuals, including children and adolescents, worldwide. To ensure that the new Barbie doll accurately represents the lived experience of individuals managing this condition, Mattel partnered with Aide aux Jeunes Diabétiques, a French charity that supports young people with diabetes, and Breakthrough T1D (formerly JDRF), a global organisation focused on research, advocacy, and improving care for people with T1D. These collaborations helped ensure that the doll's features, including the use of real-world medical devices such as a continuous glucose monitor and insulin pump, reflected the current standards in diabetes management. The aim was to promote inclusion and awareness by representing the everyday reality of children with T1D. The new Barbie doll features: Continuous glucose monitor: The doll wears a continuous glucose monitor on her arm to support blood glucose management in T1D. These small, wearable devices measure glucose levels continuously throughout the day. The sensor is secured with heart-shaped medical tape in Barbie pink, and the doll includes a phone that displays a monitoring app used to track glucose levels in real time. The doll wears a continuous glucose monitor on her arm to support blood glucose management in T1D. These small, wearable devices measure glucose levels continuously throughout the day. The sensor is secured with heart-shaped medical tape in Barbie pink, and the doll includes a phone that displays a monitoring app used to track glucose levels in real time. Insulin pump: Attached at her waist, the insulin pump is a small wearable device that delivers insulin automatically, as needed. This method of insulin administration is widely used by individuals with T1D to maintain stable blood glucose levels. Attached at her waist, the insulin pump is a small wearable device that delivers insulin automatically, as needed. This method of insulin administration is widely used by individuals with T1D to maintain stable blood glucose levels. Blue polka dot outfit: The doll wears a polka dot top and matching ruffled skirt. Both the blue colour and circular print are recognised global symbols for diabetes awareness, including the blue circle associated with World Diabetes Day. The doll wears a polka dot top and matching ruffled skirt. Both the blue colour and circular print are recognised global symbols for diabetes awareness, including the blue circle associated with World Diabetes Day. Pastel blue handbag: The doll carries a pastel blue handbag intended for essential items, such as diabetes supplies or snacks. This detail reflects the everyday practical needs of individuals managing T1D, including the need to prevent or treat hypoglycaemia when away from home. Ambassadors To launch its Barbie doll featuring T1D, Mattel chose the French karate champion, Alizée Agier, as ambassador. Agier won the world championship in 2014 and European titles in 2019 and 2024. She was diagnosed with T1D at the age of 19 years and has since become a strong advocate for awareness and inclusion. 'It's not diabetes that defines me, but what I do with it. As the campaign's ambassador, she inspires thousands of young people — whether ill or not — to believe in their potential,' Agier said. Mattel also honoured two global role models and T1D advocates: Peloton instructor Robin Arzón in the US and model Lila Moss in the UK with personalised Barbie dolls. Arzón is known internationally for her work as a fitness leader and author, while Moss is a fashion model and daughter of the British supermodel Kate Moss. Both women live with T1D and use their public platforms to raise awareness and improve visibility of the condition. Arzón presented a new Barbie doll with T1D, along with her custom Barbie doll, during an event at Peloton Studios in New York City. Members of the T1D community welcomed the event as a positive step towards inclusion. 'After being diagnosed with T1D a decade ago, I've found a lot of purpose in advocating for people with the condition and educating others about it because knowledge is power — especially for young minds,' said Arzón. 'It's an absolute honour to receive a Barbie doll as a part of the brand's efforts to grow awareness and representation surrounding T1D so that we can help show kids that all types of challenges give us all the more reason to push forward and achieve our dreams.' Moss said, 'I am proud to use my platform to educate around T1D and show that being different is cool. Receiving messages from people who see my patches and feel represented means everything to me. To be able to now see Barbie dolls with T1D, and to receive a Barbie doll that visibly looks like me, even wearing her patches, is both surreal and special.' The Barbie Fashionistas line now includes more than 175 dolls, offering a wide range of skin tones, eye colours, hair textures, body types, fashion styles, and medical conditions. The collection featured dolls with visual impairment, dolls with Down syndrome, and dolls with hearing aids. In 2020, Barbie began a multiyear research collaboration with Cardiff University to explore how doll play supports children's development. According to the company, early findings suggest that playing with dolls may help children develop empathy, build social skills, and imagine a future in which everyone has equal opportunities. Details are reported on the Mattel corporate website.
Yahoo
17 hours ago
- Yahoo
Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press Release Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan Triggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients, which will start shortly, plus this safety trial, is required for submission for marketing approval of NCX 470 in Japan. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.'Thanks to our continuing collaborative efforts after Kowa received approval to initiate this trial, we are very pleased to announce that the first patient has been enrolled. The Phase 3 trials in Japan are being managed and financed by Kowa, and only one confirmatory Phase 3 trial is expected to be needed to make a submission for marketing approval of NCX 470 in Japan.' said Doug Hubatsch, EVP Scientific Officer of Nicox. The trial announced today is a safety trial and is detailed here: JRCT Safety Trial NCX 470. The 500 patient confirmatory trial is expected to start shortly and is detailed here: JRCT Confirmatory Trial NCX NCX 470NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development programs in the U.S., China and Japan for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. All patients have completed the second Phase 3 clinical trial, Denali, and topline results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. A separate Phase 3 clinical program is underway to support Japanese approval. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia and to Kowa in the rest of the world. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NCX470KowaFPFVAugust2025_PR_FINAL